VRDN
NASDAQ · Biotechnology
Viridian Therapeutics Inc
$28.35
+1.16 (+4.27%)
Performance
1D
—
1W
—
1M
—
3M
-11.07%
6M
+31.19%
1Y
+100.21%
YTD
-7.59%
Open$27.24
Previous Close$27.19
Day High$28.59
Day Low$27.10
52W High$34.29
52W Low$9.90
Volume—
Avg Volume1.06M
Market Cap2.81B
P/E Ratio—
EPS$-4.00
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$31.51
Below
SMA 200
$22.43
Above
RSI (14)
17.6
Oversold
Trend
Golden Cross
Bullish
Analyst Ratings
Strong Buy
25 analysts
Price Target
+125.2% upside
Current
$28.35
$28.35
Target
$63.84
$63.84
$43.31
$63.84 avg
$68.31
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 87.04M | 891.8K | 430.67M |
| Net Income | -420,842,492 | -725,406,968 | -19,976,292 |
| Profit Margin | -483.6% | -84,917.7% | -4.6% |
| EBITDA | -447,812,496 | -846,793,579 | -30,128,222 |
| Free Cash Flow | — | — | -23,390,816 |
| Rev Growth | +242.1% | -53.3% | -2.2% |
| Debt/Equity | 0.12 | 0.03 | 0.27 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |